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Abstract
Nucleotide excision repair (NER) plays a critical role in the development of smoking-related cancers. We hypothesize 
that mRNA expression levels of NER genes are associated with risk of the squamous cell carcinoma of head and neck 
(SCCHN). To test this hypothesis, we conducted a case-control study of 260 SCCHN patients and 246 cancer-free controls 
by measuring the mRNA expression levels of eight core NER genes in cultured peripheral lymphocytes. Compared with the 
controls, cases had statistically significantly lower expression levels of DDB1 and ERCC3 (P = 0.015 and 0.041, respectively). 
Because DDB1 and ERCC3 expression levels were highly correlated, we used DDB1 for further multivariate analyses and 
modeling. After dividing the subjects by controls’ quartiles of expression levels, we found an association between an 
increased risk of SCCHN and low DDB1 expression levels [adjusted ORs and 95% CIs: 1.92 and 1.11–3.32, 1.48 and 0.85–2.59, 
2.00 and 1.15–3.45 for the 2nd–4th quartiles, respectively, compared with the 1st quartile; Ptrend = 0.026]. We also identified 
a multiplicative interaction between sex and DDB1 expression levels (P = 0.007). Finally, the expanded model with gene 
expression levels, in addition to demographic and clinical variables, on SCCHN risk was significantly improved, especially 
among men. In conclusion, reduced DDB1 expression levels were associated with an increased risk of SCCHN. However, 
these results need to be validated in larger studies.
Introduction
Squamous cell carcinoma of head and neck (SCCHN) is among 
the most common malignancies worldwide, which includes 
cancers of the oral cavity, larynx and pharynx (1,2). In the United 
States, the estimated number of new SCCHN cases has been 
increasing from 48 010 in 2009 to 61 760 in 2016, according to the 
American Cancer Society (3–5). Although it is well established 
that cigarette smoking and alcohol use are major risk factors 
for SCCHN in general as well as prior HPV type 16 infection for 
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oropharyngeal cancer, only a small fraction of those who have 
the history of smoking, alcohol use or HPV infection develop one 
of these cancers in their lifetime, suggesting that there may be 
heterogeneity in SCCHN susceptibility (6,7).
Numerous chemicals in tobacco smoke can cause dam-
age to cellular DNA (8,9). For example, one of these chemicals 
is benzo (a) pyrene diol epoxide (BPDE) that is a bio-activated 
form of benzo (a) pyrene, which is a classic tobacco carcinogen 
that can induce irreversible damage to DNA through the forma-
tion of covalent binding or oxidation by forming DNA adducts 
(10–12). Several DNA repair pathways have evolved to repair these 
adducts (13–15), among which nucleotide excision repair (NER) 
is a major and well-studied but complex and versatile mecha-
nism (16). NER essentially uses eight core genes to restore the 
damaged DNA to normal one in eukaryotes. The basic steps in 
NER include: damage recognition (DDB1, XPA and XPC), unwind-
ing the duplex and kinetic proofreading (ERCC2/XPD and ERCC3/
XPB), dual incision (ERCC1, ERCC4/XPF and ERCC5/XPG), repair 
synthesis and ligation (17). Functional mutations in any of these 
genes may lead to abnormal NER and subsequently increase 
susceptibility to cancer. In humans, for example, several rare 
disorders are associated with NER deficiency (18), including 
xeroderma pigmentosum (XP) that is an autosomal recessive 
disease with a defective NER (19). XP patients have mutations in 
at least one of these eight NER genes and consequently have a 
remarkably increased risk of developing sun-light induced skin 
cancers (20). In addition to NER, double strand break (DSB) repair 
may also play an important role in HPV-positive oropharyngeal 
cancer, and we recently showed that reduced DSB repair was 
associated with increased risk of SCCHN as well (21).
In an early study of 55 SCCHN patients and 61 healthy con-
trols by the host-cell reactivation (HCR) assay that measures 
DNA repair capacity (DRC), it was reported that the cases had a 
significantly lower DRC than that of controls, and subjects with 
a reduced DRC had a greater than 2-fold increased risk of devel-
oping head and neck cancer, compared with those with a higher 
DRC (22). These results were confirmed later by a much larger 
study of 744 SCCHN patients and 753 controls (23). To further 
understand the underling molecular mechanism, we conducted 
a pilot study of 57 SCCHN patients and 105 cancer-free controls 
and reported that an increased risk of SCCHN was associated 
with reduced mRNA expression levels of NER genes in lympho-
cytes (24). However, previous association studies of NER mRNA 
expression and risk of SCCHN had relatively limited numbers 
of cases and controls, and also we were not able to measure the 
expression of DDB1, ERCC2, ERCC4 or XPA, because the sequences 
of these genes were unknown at that time. Thus, studies of a 
larger sample size are required to further evaluate the previ-
ously reported association between NER gene expression and 
SCCHN risk. Therefore, we conducted a larger case-control study 
to test associations between mRNA expression levels of eight 
core NER genes and risk of SCCHN. In the present study, because 
the precise molecular mechanism underlying HPV-positive oro-
pharyngeal cancer is still not well documented, we specifically 
tested expression levels of genes in the NER pathway.
Materials and Methods
Study subjects
The SCCHN study cases and controls were recruited from The University 
of Texas M.D. Anderson Cancer Center between 2002 and 2012 for a molec-
ular epidemiology study, and a subset of 506 subjects (260 cases and 246 
controls) were selected for the present study, because they had additional 
blood samples for culture of T-lymphocytes that were sufficient for total 
RNA extraction. In order to evaluate selection bias, we compared the case-
control samples included in the study with the samples excluded. The 
SCCHN patients were recruited, if they meet the following criteria: newly 
diagnosed, 18 years and older, untreated, no other previous cancers but 
diagnosed with histologically confirmed SCCHN. The cancer-free controls 
were recruited among visitors accompanying patients to clinics other 
than the Head and Neck clinic where cases were recruited; they were 
frequency-matched with cases on age and sex and had no blood transfu-
sion in the last six months as well as no history of any previous cancers. 
In order to avoid genetic heterogeneity of different races, the subjects 
included in the analysis were all non-Hispanic white. A written informed 
consent was obtained from eligible patients and controls. Subjects who 
had smoked more than 100 cigarettes during their lifetime were defined 
as smokers, of which those who had stopped smoking at least 12 months 
were defined as former smokers and remaining was considered current 
smokers; others were considered never smokers. Subjects who consumed 
alcoholic beverages at least weekly for one year were defined as drink-
ers, of which those who had stopped drinking more than 12 months were 
defined as former and the remaining was considered current drinkers; 
others were considered never drinkers. Ever smokers and ever drink-
ers were also used to describe former and current smokers or drinkers, 
respectively. Each subject donated a 30  ml blood sample drawn into a 
heparinized tube before receiving treatment for cases and when consent 
was given for controls. The study protocol was approved by M.D. Anderson 
Institutional Review Board.
Quantitative real-time PCR
The mRNA expression levels of eight core NER genes were examined by 
quantitative real-time PCR using the total RNA that was isolated from 
each sample of lymphocytes from the 506 subjects with the TRIzol reagent 
(InvitrogenTM, Carlsbad, CA). The PCR was performed using the ABI Prism 
7900HT Sequence Detection System (Applied Biosystems, Foster City, CA) 
by TaqMan gene expression assays with the master mix reagent (Applied 
Biosystems, Foster City, CA) according to the manufacturer’s instructions 
which was also described previously (25,26). Each amplification reaction 
was performed in a final volume of 5 μl containing 5 ng of the comple-
mentary DNA, 0.25 μl primers and 2.5 μl Master mix. The PCR reaction 
was carried out in 384-well optical plates with a final volume of 5  μl 
reaction mixtures. Thermal cycling conditions were as follows: 95°C for 
5 min, followed by 40 cycles of denaturation at 95°C for 15 s, and anneal-
ing/extension at 60°C for 1 min. The 18S expression was assessed as an 
internal control to account for differences of complementary DNA. Each 
sample was analyzed in duplicate, and if the coefficient of variation of all 
reactions was <5%, the mean values of the duplicates were used. When 
coefficient of variation was >5%, the assay was repeated and the samples 
with new coefficient of variation >5% were removed. The threshold cycle 
or Ct value was the PCR cycle at which a significant increase in fluores-
cent signal was first detected. Ct values form the basis for quantitative 
comparison of genes in the real-time PCR. The expression levels of eight 
NER genes relative to that of 18S were calculated by delta Ct (ΔCt). The ΔCt 
value was the Ct value of the target gene subtracted its Ct value of 18S, 
ΔCt = Ct (Gene) − Ct (18S). Therefore, the smaller the ΔCt values, the higher 
expression levels of the target mRNA.
Statistical analysis
The Chi-square test was used to evaluate differences in selected demo-
graphic variables, smoking and alcohol consumption between cases and 
Abbreviations 
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controls. Student’s t-test, Wilcoxon rank-sum test or ANOVA were used to 
compare differences in the relative mRNA expression levels analyzed as a 
continuous variable among groups. In addition, we performed a stepwise 
logistic regression analysis to explore the best model to predict SCCHN 
risk. We used the quartiles of ΔCt values in the control group as cutoff val-
ues for calculating crude odds ratio (OR) and their 95% confidence intervals 
(CI). The associations of NER genes mRNA expression levels with SCCHN 
risk were estimated by computing ORs and CIs from logistic regression 
models. These analyses were performed with or without adjustment for 
age (in years), sex (female versus male), smoking (never, former or current) 
and alcohol use (never, former or current).
Further stratification analyses were performed to identify effect modi-
fication of related NER genes and selected variables. A multiplicative inter-
action was suggested when OR11 > OR10 × OR01, in which OR11 was the OR 
when both factors were present, OR01 was the OR when only factor 1 was 
present, and OR10 was the OR when only factor 2 was present. We evalu-
ated the interactions by looking for a multiplicative scale using standard 
unconditional logistic regression models.
To assess the improvement of SCCHN risk models by gene expression 
levels, we compared the area under the receiver operating characteristic 
(ROC) curve (AUC) among three risk models: the baseline model includ-
ing only epidemiologic variables [e.g. age, sex, smoking and drinking sta-
tus], the NER model including the epidemiologic variables and NER gene 
expression (continuous variable), and the interaction model including the 
epidemiologic variables, NER gene expression and interaction term. We 
further calculated the AUC upon stratification by related covariates. All 
tests were two-sided and P < 0.05 was considered significant. All statistical 
analyses were performed with SAS software (version 9.4; SAS Institute, 
Inc., Cary, NC).
Results
Characteristics of the study population
The summary of the distributions of selected characteristics of 
cases and controls is presented in Table 1. There were no sig-
nificant differences in the distributions of age and sex between 
cases and controls. Furthermore, no significant differences were 
observed in the distributions of age, sex, smoking and drinking 
status between the included and excluded subjects, except for 
the distribution of drinkers in controls. Even though the differ-
ence in the distribution of drinkers between the included and 
excluded controls was statistically significant, the two control 
groups both had more never drinkers than current drinkers and 
more current drinkers than former drinkers (Supplementary 
Table  1). These results suggest there was no selection bias in 
the included samples. The average age was 58.4  years for the 
case subjects (median, 58; range, 22–86) and 55.7 years for the 
control subjects (median, 56; range, 25–86). Of all the subjects, 
74.2% of cases and 78.1% of controls were male, 64.6% of cases 
and 49.2% of controls were ever smokers and 73.1% of cases and 
61.8% of controls were ever drinkers. There were more current 
smokers (30.8%) and current drinkers (48.9%) in cases than in 
controls (11.4% and 37.8%, respectively). The primary SCCHN 
of 260 patients included the oral cavity (80, 30.8%), oropharynx 
(142, 54.6%), hypopharynx (6, 2.3%) and larynx (32, 12.3%).
Differences in NER mRNA expression levels between 
cases and controls
The cases showed lower relative mean expression levels in 
seven of the eight core NER genes analyzed than did controls, 
except for XPA (Table 2). In Student’s t-test or Wilcoxon rank-
sum test for differences in NER mRNA expression levels between 
cases and controls, only DDB1 and ERCC3 levels were statisti-
cally significantly lower in cases than in controls (P = 0.015 and 
P = 0.041, respectively; Figure 1A). Because the expression lev-
els of the eight NER genes were measured at the same time, 
they were likely to be correlated with each other. As shown in 
Supplementary Table  2, mRNA expression levels of all eight 
NER genes were statistically significantly correlated with each 
other. Subsequently, when we included the expression levels of 
both DDB1 and ERCC3 in the stepwise logistic regression analy-
sis after adjustment for age, sex, smoking and alcohol use, only 
DDB1 remained in the final model (P = 0.017).
Stratification analyses of mRNA expression levels of 
DDB1 and ERCC3 by selected variables
Stratification analyses of DDB1 and ERCC3 expression levels 
revealed that patients in subgroups of the age ≤ 56, male, former 
smokers and current drinkers exhibited significantly lower mean 
expression levels of DDB1 than did controls (P = 0.030, P < 0.001, 
P = 0.021, and P = 0.012, respectively, Table 3). Likewise, patients 
in subgroups of the age ≤ 56, male, and never smokers exhibited 
significantly lower mean expression of ERCC3 than did controls 
(P = 0.013, P = 0.015, and P = 0.042, respectively, Table 3). In both 
cases and controls, women had lower expression levels of DDB1 
and ERCC3 than did men, but the sex differences in the expres-
sion levels were only significant in control groups (P < 0.001 and 
P = 0.004, respectively, Table 3). Moreover, there were more ever 
smokers and ever drinkers in males than in females, but the 
difference was only statistically significant in alcohol drinkers 
(P < 0.001), and not statistically significant in smokers (P = 0.387, 
Supplementary Table  3). There were no significant differences 
in the expression levels of DDB1 and ERCC3 by tumor sites, sug-
gesting that expression levels of DDB1 and ERCC3 may not be 
different among tumors of SCCHN (Supplementary Table 4).
Associations between NER mRNA expression levels 
and risk of SCCHN
To estimate SCCHN risk, the relative expression levels were 
grouped into quartile values of the controls (Table 4 and 
Supplementary Table 5). The crude ORs for SCCHN risk associated 
with relative expression levels of DDB1 in the second quartile, 
Table 1. Distributions of demographic variables and tumor charac-
teristics between 260 SCCHN cases and 246 cancer-free controls
Variable Case (n = 260) Control (n = 246) P*
Age 0.258
 Median (range) 58 (22–86) 56 (25–86)
 ≤56 118 (45.4) 124 (50.4)
 >56 142 (54.6) 122 (49.6)
Sex 0.314
 Female 67 (25.8) 54 (21.9)
 Male 193 (74.2) 192 (78.1)
Smoking <0.001
 Never 92 (35.4) 125 (50.8)
 Former 88 (33.8) 93 (37.8)
 Current 80 (30.8) 28 (11.4)
Drinking 0.014
 Never 70 (26.9) 94 (38.2)
 Former 63 (24.2) 59 (24.0)
 Current 127 (48.9) 93 (37.8)
Tumor site
 Oral cavity 80 (30.8)
 Oropharynx 142 (54.6)
 Larynx/Hypopharynx 38 (14.6)
SCCHN, squamous cell carcinoma of the head and neck.
*Chi-square tests for the distributions comparison of the demographic vari-
ables between cases and controls.
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third quartile and fourth quartile were 2.00 (95% CI, 1.19–3.37), 
1.64 (95% CI, 0.96–2.80) and 2.03 (95% CI, 1.20–3.42), while the 
corresponding crude ORs for ERCC3 were 1.64 (95% CI, 0.98–2.74), 
1.34 (95% CI, 0.79–2.27) and 1.93 (95% CI, 1.16–3.21), respectively, 
compared with the first quartile (the highest expression levels of 
the gene). After adjusting for age, sex, smoking status and alco-
hol consumption in multivariate logistic regression analysis, 
the ORs of DDB1 and ERCC3 remained essentially unchanged. 
When continuous ΔCt values were used in the logistic regres-
sion model with adjustment for all covariates, there was also 
a dose-response relationship between the reduced expression 
levels and the increased SCCHN risk for both DDB1 (Ptrend = 0.026) 
and ERCC3 (Ptrend = 0.036).
Interactions between DDB1 expression levels and 
selected variables
We further assessed possible interactions on a multiplicative 
scale between expression levels of DDB1 and selected variables 
listed in Table 1. The multiplicative interaction was tested when 
we included the interaction term (i.e., relative expression levels 
of DDB1 × each of the risk factors) in a multivariate regression 
model that also included the main effects of NER gene expres-
sion levels and other covariates. We found that sex (male ver-
sus female) had a significantly multiplicative interaction with 
relative expression levels of DDB1 (P  =  0.007, Table 3), but did 
not find any for ERCC3, in association with SCCHN risk. To fur-
ther unravel these multiplicative interactions, we stratified the 
adjusted ORs by sex. It was apparent that ORs for the relative 
expression levels of DDB1 by Q1 and Q3 in groups of males were 
greater than those of females (Figure 1B).
We further assessed the prediction performance of models 
integrating demographic variables and gene expression levels 
on SCCHN using the ROC curves that measure the effect of DDB1 
expression levels and the interaction with sex in three dimen-
sions. The AUC was significantly improved in the model that 
included the combined effect of DDB1 expression levels and 
the interaction with sex, compared with the model that did not 
(Figure 2A, P = 0.033). Furthermore, the AUC was insignificantly 
improved in male subjects that included the combined effect of 
DDB1 expression levels and the interaction with sex, compared 
with the model that did not (Figure 2B, P = 0.083).
Discussion
In this larger case-control study, we further confirmed our previ-
ous studies that reduced NER gene expression was associated 
with an increased risk of SCCHN. Our results showed that the 
reduced relative mRNA expression levels of the two NER genes 
(e.g. DDB1 and ERCC3) were associated with an increased risk 
of SCCHN. We further assessed interactions between DDB1 
expression levels and selected variables and found that sex had 
a significant multiplicative interaction with DDB1 expression 
Figure  1. (A) Relative mRNA expression levels of eight NER genes between 
SCCHN patients and healthy controls. Quantitative real-time PCR was used to 
measure the relative expressions of eight NER genes. Housekeeping gene 18S 
was used as the reference. The threshold cycle or Ct value is the PCR cycle at 
which a significant increase in fluorescent signal is first detected. The expres-
sion levels of eight NER genes relative to that of 18S were calculated by ΔCt. 
ΔCt = Ct (Gene) − Ct (18S). The smaller the ΔCt value, the higher the level of the 
measured target mRNA (*P < 0.05). (B) Modification effects of DDB1 by sex.
Table 2. Comparison of the mRNA expression levels of eight core nucleotide excision repair genes between the cases and controls
Gene
Mean ± SD Median/IQR Difference
PCase (n = 260) Control (n = 246) Case (n = 260) Control (n = 246) Case − Control
DDB1 18.44 ± 2.20 17.95 ± 2.32 18.29/3.32 17.93/3.75 0.49 0.015*
ERCC1 19.29 ± 2.17 18.95 ± 2.19 19.32/3.55 18.76/3.38 0.34 0.125
ERCC2 21.54 ± 2.24 21.30 ± 2.05 21.65/3.66 21.50/3.53 0.24 0.243
ERCC3 19.52 ± 2.05 19.09 ± 2.08 19.54/3.21 19.25/3.09 0.43 0.041
ERCC4 21.90 ± 2.15 21.73 ± 2.33 22.10/3.57 21.67/3.75 0.17 0.568
ERCC5 20.07 ± 1.96 19.99 ± 1.88 20.16/3.06 20.07/3.02 0.08 0.670
XPA 20.45 ± 2.06 20.47 ± 1.96 20.33/3.50 20.41/2.88 -0.01 0.813
XPC 20.58 ± 2.06 20.48 ± 2.34 20.46/3.32 20.66/3.21 0.10 0.855
The expression levels of eight nucleotide excision repair genes were calculated by ΔCt values, the smaller the ΔCt represents the higher expression levels of the 
target mRNA. P value in Wilcoxon rank-sum tests. IQR, interquartile range; SD, standard deviation.
*P value in two-sided t-tests.
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on SCCHN risk. Moreover, the AUC model suggested that the 
combined effect of DDB1 and its interaction with sex further 
improved the risk prediction.
In previous studies, we measured the DRC of SCCHN cases 
and healthy controls in their peripheral lymphocytes by using 
the HCR assay; the results suggested that suboptimal DRC was 
associated with risk of developing SCCHN (22,23). Later, another 
study demonstrated a correlation between NER mRNA expres-
sion levels and suboptimal DRC phenotype in the lymphocytes 
(27). Subsequently, we developed a multiplex RT-PCR to measure 
the association between mRNA expressions of five NER genes 
(ERCC1, ERCC3, ERCC5, CSB and XPC) and risk of SCCHN (28). The 
relative mRNA expression levels of ERCC1, ERCC3, ERCC5 and CSB 
were significantly lower in cases than in controls, and the risk 
of SCCHN associated with low expressions of these genes was 
higher by 2- to 6-fold (24). However, we were not able to measure 
the expressions of DDB1, XPA, ERCC2 and ERCC4, because at that 
time the sequences of these genes were unknown. Moreover, 
the sample size of that study was relatively small, and most 
positive results in studies with small samples were not sub-
stantiated in later larger studies (29,30). In the current study, 
we confirmed that reduced expression of ERCC3 was associated 
with SCCHN risk, with additional finding for DDB1. These results 
further support the notion that altered mRNA levels, which may 
have an effect on the NER capacity, may contribute to risk of 
SCCHN. Moreover, as the HPV infection is the main risk factor 
for oropharyngeal cancer, we performed a case–case analysis of 
109 patients who had both the available HPV data and mRNA 
expression levels, of which 64 patients with oropharyngeal 
cancer. There were no significant differences in the expression 
Table 3. Stratification analyses of mRNA expression levels of DDB1 and ERCC3 between SCCHN cases and controls
Variable
DDB1 (Mean ± SD)
P* P^
ERCC3 (Mean ± SD)
P* P^Case (n = 260) Control (n = 246) Case (n = 260) Control (n = 246)
Age 0.890 0.920
 ≤56 18.49 ± 2.19 17.88 ± 1.26 0.030 19.65 ± 2.01 19.05 ± 1.81 0.013**
 >56 18.40 ± 2.22 18.02 ± 2.49 0.191 19.41 ± 2.07 19.13 ± 2.33 0.626**
 P* 0.739 0.641 0.341 0.481**
Sex 0.007 0.138
 Female 18.59 ± 2.32 19.08 ± 2.09 0.233 19.76 ± 2.21 19.81 ± 1.77 0.877
 Male 18.39 ± 2.16 17.63 ± 2.29 0.001 19.44 ± 1.99 18.89 ± 2.13 0.015**
 P* 0.511 <0.001 0.293** 0.004
Smoking 0.493 0.243
 Never 18.37 ± 2.30 17.82 ± 2.50 0.098 19.54 ± 2.08 18.93 ± 2.22 0.042
 Former 18.71 ± 2.20 17.97 ± 2.11 0.021 19.64 ± 2.00 19.16 ± 1.87 0.160**
 Current 18.22 ± 2.08 18.46 ± 2.21 0.597 19.36 ± 2.07 19.59 ± 2.10 0.623
 P*** 0.322 0.412 0.675 0.403**
Drinking 0.255 0.626
 Never 18.42 ± 2.55 17.93 ± 2.49 0.219 19.50 ± 2.31 18.95 ± 2.20 0.224**
 Former 18.52 ± 1.87 18.41 ± 2.33 0.781 19.58 ± 1.86 19.45 ± 2.11 0.720
 Current 18.41 ± 2.16 17.66 ± 2.12 0.012 19.50 ± 2.00 19.00 ± 1.89 0.063
 P*** 0.944 0.153 0.904** 0.306
The expression levels of eight nucleotide excision repair genes were calculated by ΔCt, the smaller the ΔCt values represents the higher expression levels of the 
target mRNA. SCCHN, squamous cell carcinoma of the head and neck.
*P value in two-sided t-tests.
**P value in Wilcoxon rank-sum tests.
***P value in one-way ANOVA.
^P value in multiplicative interaction analysis between selected variables and genes in relation to SCCHN risk.
Table 4. Logistic regression analysis of mRNA expression levels of eight core NER genes in SCCHN cases and controls
NER Genes Quantile mRNA Levels*** Case n (%) Control n (%) Crude OR (95% CI) Adjusted OR* (95% CI)
DDB1 ≤16.09 39 (15.0) 61 (25.0) 1.00 (Ref) 1.00 (Ref)
16.10–17.93 78 (30.0) 61 (25.0) 2.00 (1.19–3.37) 1.92 (1.11–3.32)
17.94–19.76 64 (24.6) 61 (25.0) 1.64 (0.96–2.80) 1.48 (0.85–2.59)
≥19.77 79 (30.4) 61 (25.0) 2.03 (1.20–3.42) 2.00 (1.15–3.45)
 P** 0.016 0.026
ERCC3 ≤17.50 44 (16.9) 61 (25.0) 1.00 (Ref) 1.00 (Ref)
17.51–19.25 72 (27.7) 61 (25.0) 1.64 (0.98–2.74) 1.66 (0.97–2.85)
19.26–20.59 59 (22.7) 61 (25.0) 1.34 (0.79–2.27) 1.32 (0.76–2.29)
≥20.60 85 (32.7) 61 (25.0) 1.93 (1.16–3.21) 1.90 (1.12–3.24)
 P** 0.022 0.036
CI, confidence interval; NER, nucleotide excision repair; OR, odds ratio; SCCHN, squamous cell carcinoma of the head and neck.
*Adjusted for age, sex, smoking and alcohol status.
**P value in trend test by continuous mRNA expression levels.
***Expression levels by quartile based on the quartile values of control subjects. The expression levels of eight NER genes were calculated by ΔCt, the smaller the ΔCt 
values represent the higher expression levels of the target mRNA.
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levels of all eight NER genes by the HPV status for oropharyn-
geal cancer patients nor for all the patients except for ERCC4, 
suggesting that expression levels of eight NER genes were not 
correlated with the HPV status (Supplementary Table 6).
Previous studies have suggested that women have a higher 
risk of developing smoking-related cancers than men do, even 
at similar levels of exposure (23,31,32). In the present study, we 
showed that a significantly lower mRNA expression levels of 
DDB1 and ERCC3 in female controls than in male controls, but 
not in the cases (Table 3), which is also consistent with our pre-
vious results on DRC (23,33). Furthermore, we found a modified 
effect of sex on DDB1, suggesting that the association between 
the reduced expression levels of DDB1 and risk of SCCHN dif-
fered between sexes. Subsequently, we estimated the ORs of 
DDB1 for both sexes and found that the adjusted ORs for DDB1 
in males were greater than in females, indicating that males 
might have a higher risk of developing SCCHN with a lower 
DDB1 mRNA expression (Figure 1B).
Recently more data showed phenotypic and genotypic mark-
ers have been tentatively added to the AUC models (34–36). 
Previously, we reported the improvement on prediction of lung 
cancer risk by adding two markers of DRC in the AUC model, 
and the results showed the expanded models were statisti-
cally significantly better than the baseline models (37). Later, 
we assessed the performance of DRC in SCCHN risk prediction 
model and found that the addition of DRC improved the AUC, 
which was more evident in never smokers than in ever smok-
ers (23). In the present study, we found further improvement in 
AUC by adding the combined effect of expression of DDB1 and 
its interaction with sex, compared with baseline model. Taken 
together, these results suggest that reduced DDB1 mRNA expres-
sion may play a more important role in SCCHN risk, especially 
in male subjects. Future mechanistic studies are needed for the 
role of expression of these genes in the etiology of SCCHN.
The protein encoded by DDB1 recognizes some UV-damaged 
DNA lesions and initiates the NER process, but some studies 
suggested that DDB1 might be involved in a general cellular 
response to DNA damage rather than a specific repair pathway 
(38–40). In the present study, we found that the addition of DDB1 
improved the sensitivity of the expanded model in male sub-
jects. The possible reasons behind this are: on one hand, there 
might be genetic differences relating the gene expression of 
DDB1 between men and women; on the other hand, the control 
group has more ever smokers (49.2%) and ever drinkers (61.8%) 
than the general population, in which male subjects tend to 
have more smokers and alcohol users than female subjects. The 
ERCC3 gene encodes a DNA-dependent ATPase-helicase subunit 
of the transcription factor IIH, which is involved in transcription 
and NER (41,42). Our data suggested an increased risk of SCCHN 
associated with reduced expression levels of ERCC3, and the cur-
rent results were consistent with those of previously published 
SCCHN studies as well as a lung cancer study in which some tag 
SNPs of ERCC3 were shown to serve as biomarkers of suscepti-
bility to lung cancer (24,32,41).
There are both strengths and limitations in the current study. 
First, because the quantitative real-time PCR assay provides a 
more precise quantitative measurement of mRNA levels than 
conventional multiplex reverse transcriptase PCR, the current 
study provided more accurate measurements than the previ-
ous pilot SCCHN study. In addition, this method requires a much 
small amount of total RNA, and the peripheral blood lymphocytes 
are easier to obtain from population-based studies. Therefore, the 
quantitative real-time PCR assay using peripheral blood lympho-
cytes is an optimal assay for future epidemiologic studies. Second, 
like all other hospital-based studies, the control group may not 
be representative of the general population. In the current study, 
the control group had 49.2% ever smokers and 61.8% ever drink-
ers, much greater than those of the general population. To over-
come possible selection bias from a hospital-based case-control 
studies, future studies may need a much larger sample size and 
recruit the controls from the community-based population. 
Third, our results showed sex, but not smoking and drinking, had 
a statistically significant interaction with SCCHN risk. Although 
smoking and drinking are the two major biological plausible fac-
tors for SCCHN, different hormone levels by sex may have played 
a role in SCCHN, which should be further investigated in future 
studies. Lastly, although we found that reduced expression levels 
of DDB1 and ERCC3 were associated with SCCHN risk, the exact 
mechanisms by which DDB1 and ERCC3 influence SCCHN risk are 
still unknown and to be investigated.
Supplementary material
Supplementary data are available at Carcinogenesis online.
Figure 2. Overall and stratified receiver operating characteristic (ROC) curves by sex calculated in multivariate logistic models. (A) The area under the curve (AUC) was 
significantly improved in the model that included the combined effect of DDB1 expression levels and the interaction with sex, compared with the model that did not 
(P = 0.033). (B) The AUC was insignificantly improved in male subjects that included the combined effect of DDB1 expression levels (P = 0.083). (C) The AUC was insig-
nificantly improved in female subjects (P = 0.255).
510 | Carcinogenesis, 2017, Vol. 38, No. 5
Funding
This study was supported in part by National Institutes of 
Health (R01 ES 11740 and R01 CA 131274 to Q.W.); and a start-up 
funds to (Q.W.) from Duke Cancer Institute. QW was also sup-
ported from the Duke University Medical Center and the Duke 
Cancer Institute as part of the P30 Cancer Center Support of 
National Institutes of Health (CA014236). Its contents are solely 
the responsibility of the authors and do not necessarily repre-
sent the official views of the National Institutes of Health.
Acknowledgments
We thank Li-E Wang, Margaret Lung and Jessica Fiske for their 
assistance in recruiting the subjects and gathering the question-
naire information.
Conflict of Interest Statement: None declared.
Reference
 1. Simard, E.P. et al. (2014) International trends in head and neck cancer 
incidence rates: differences by country, sex and anatomic site. Oral 
Oncol., 50, 387–403.
 2. Wissinger, E. et al. (2014) The economic burden of head and neck can-
cer: a systematic literature review. Pharmacoeconomics, 32, 865–882.
 3. Jemal, A. et al. (2009) Cancer statistics, 2009. CA. Cancer J. Clin., 59, 225–
249.
 4. Siegel, R.L. et al. (2016) Cancer statistics, 2016. CA. Cancer J. Clin., 66, 
7–30.
 5. Torre, L.A. et al. (2015) Global cancer statistics, 2012. CA. Cancer J. Clin., 
65, 87–108.
 6. Hashibe, M. et al. (2007) Alcohol drinking in never users of tobacco, cig-
arette smoking in never drinkers, and the risk of head and neck cancer: 
pooled analysis in the International Head and Neck Cancer Epidemiol-
ogy Consortium. J. Natl. Cancer Inst., 99, 777–789.
 7. Hashibe, M. et al. (2009) Interaction between tobacco and alcohol use 
and the risk of head and neck cancer: pooled analysis in the Interna-
tional Head and Neck Cancer Epidemiology Consortium. Cancer Epide-
miol. Biomarkers Prev., 18, 541–550.
 8. Jackson, S.P. et al. (2009) The DNA-damage response in human biology 
and disease. Nature, 461, 1071–1078.
 9. Wang, M. et al. (2013) Molecular epidemiology of DNA repair gene poly-
morphisms and head and neck cancer. J. Biomed. Res., 27, 179–192.
 10. Li, D. et  al. (2007) In vitro benzo[a]pyrene diol epoxide-induced DNA 
adducts and risk of squamous cell carcinoma of head and neck. Cancer 
Res., 67, 5628–5634.
 11. Phillips, D.H. (1983) Fifty years of benzo(a)pyrene. Nature, 303, 468–472.
 12. Xiong, P. et al. (2007) In vitro benzo[a]pyrene diol epoxide-induced DNA 
damage and chromosomal aberrations in primary lymphocytes, smok-
ing, and risk of squamous cell carcinoma of the head and neck. Int. 
J. Cancer, 121, 2735–2740.
 13. Wei, Q. et al. (1998) Reduced expression of hMLH1 and hGTBP/hMSH6: 
a risk factor for head and neck cancer. Cancer Epidemiol. Biomarkers 
Prev., 7, 309–314.
 14. Wood, R.D. et al. (2005) Human DNA repair genes, 2005. Mutat. Res., 577, 
275–283.
 15. Wood, R.D. et al. (2001) Human DNA repair genes. Science, 291, 1284–1289.
 16. Li, C. et  al. (2009) DNA repair phenotype and cancer susceptibility–a 
mini review. Int. J. Cancer, 124, 999–1007.
 17. Spivak, G. (2015) Nucleotide excision repair in humans. DNA Repair 
(Amst)., 36, 13–18.
 18. de Boer, J. et  al. (2000) Nucleotide excision repair and human syn-
dromes. Carcinogenesis, 21, 453–460.
 19. Norgauer, J. et al. (2003) Xeroderma pigmentosum. Eur. J. Dermatol., 13, 4–9.
 20. Cleaver, J.E. (2005) Cancer in xeroderma pigmentosum and related dis-
orders of DNA repair. Nat. Rev. Cancer, 5, 564–573.
 21. Liu, Z. et al. (2016) Reduced DNA double-strand break repair capacity 
and risk of squamous cell carcinoma of the head and neck–A case-
control study. DNA Repair (Amst)., 40, 18–26.
 22. Cheng, L. et al. (1998) Reduced DNA repair capacity in head and neck 
cancer patients. Cancer Epidemiol. Biomarkers Prev., 7, 465–468.
 23. Wang, L.E. et  al. (2010) Reduced DNA repair capacity for removing 
tobacco carcinogen-induced DNA adducts contributes to risk of head 
and neck cancer but not tumor characteristics. Clin. Cancer Res., 16, 
764–774.
 24. Cheng, L. et al. (2002) Expression of nucleotide excision repair genes 
and the risk for squamous cell carcinoma of the head and neck. Can-
cer, 94, 393–397.
 25. Liu, Z. et al. (2003) Overexpression of hMTH in peripheral lymphocytes 
and risk of prostate cancer: a case-control analysis. Mol. Carcinog., 36, 
123–129.
 26. Liu, Z. et  al. (2005) Methylation and messenger RNA expression of 
p15INK4b but not p16INK4a are independent risk factors for ovarian 
cancer. Clin. Cancer Res., 11, 4968–4976.
 27. Vogel, U. et al. (2000) DNA repair capacity: inconsistency between effect 
of over-expression of five NER genes and the correlation to mRNA lev-
els in primary lymphocytes. Mutat. Res., 461, 197–210.
 28. Cheng, L. et al. (1999) Expression in normal human tissues of five nucle-
otide excision repair genes measured simultaneously by multiplex 
reverse transcription-polymerase chain reaction. Cancer Epidemiol. 
Biomarkers Prev., 8, 801–807.
 29. Kumar, A. et al. (2012) Reduced expression of DNA repair genes (XRCC1, 
XPD, and OGG1) in squamous cell carcinoma of head and neck in North 
India. Tumour Biol., 33, 111–119.
 30. Ma, H. et al. (2012) Polymorphisms of XPG/ERCC5 and risk of squamous 
cell carcinoma of the head and neck. Pharmacogenet. Genomics, 22, 
50–57.
 31. Mollerup, S. et al. (2006) Sex differences in risk of lung cancer: Expres-
sion of genes in the PAH bioactivation pathway in relation to smoking 
and bulky DNA adducts. Int. J. Cancer, 119, 741–744.
 32. Muscat, J.E. et al. (1996) Gender differences in smoking and risk for oral 
cancer. Cancer Res., 56, 5192–5197.
 33. Wei, Q. et al. (2000) Repair of tobacco carcinogen-induced DNA adducts 
and lung cancer risk: a molecular epidemiologic study. J. Natl. Cancer 
Inst., 92, 1764–1772.
 34. Paynter, N.P. et  al. (2009) Cardiovascular disease risk prediction with 
and without knowledge of genetic variation at chromosome 9p21.3. 
Ann. Intern. Med., 150, 65–72.
 35. Vachon, C.M. et  al. (2007) Mammographic density, breast cancer risk 
and risk prediction. Breast Cancer Res., 9, 217.
 36. van der Net, J.B. et al. (2009) Usefulness of genetic polymorphisms and 
conventional risk factors to predict coronary heart disease in patients 
with familial hypercholesterolemia. Am. J. Cardiol., 103, 375–380.
 37. Spitz, M.R. et al. (2008) An expanded risk prediction model for lung can-
cer. Cancer Prev. Res. (Phila)., 1, 250–254.
 38. Cang, Y. et al. (2007) DDB1 is essential for genomic stability in develop-
ing epidermis. Proc. Natl. Acad. Sci. U. S. A., 104, 2733–2737.
 39. Scrima, A. et al. (2008) Structural basis of UV DNA-damage recognition 
by the DDB1-DDB2 complex. Cell, 135, 1213–1223.
 40. Tang, J.Y. et  al. (2000) Xeroderma pigmentosum p48 gene enhances 
global genomic repair and suppresses UV-induced mutagenesis. Mol. 
Cell, 5, 737–744.
 41. Hu, Z. et al. (2006) Polymorphisms in the two helicases ERCC2/XPD and 
ERCC3/XPB of the transcription factor IIH complex and risk of lung 
cancer: a case-control analysis in a Chinese population. Cancer Epide-
miol. Biomarkers Prev., 15, 1336–1340.
 42. Oh, K.S. et al. (2006) Phenotypic heterogeneity in the XPB DNA helicase 
gene (ERCC3): xeroderma pigmentosum without and with Cockayne 
syndrome. Hum. Mutat., 27, 1092–1103.
